NVV1 Stock Overview A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Novavax, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Novavax Historical stock prices Current Share Price US$8.43 52 Week High US$23.93 52 Week Low US$3.33 Beta 2.06 1 Month Change 7.54% 3 Month Change -31.91% 1 Year Change 85.84% 3 Year Change -92.52% 5 Year Change 136.69% Change since IPO -84.90%
Recent News & Updates
Forecast breakeven date moved forward to 2025 Dec 30
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Dec 10
Forecast breakeven date moved forward to 2025 Nov 15
Third quarter 2024 earnings released: US$0.76 loss per share (vs US$1.26 loss in 3Q 2023) Nov 13
Novavax, Inc. Revises Revenue Guidance for the Full Year 2024 Nov 13 Nov 13
See more updates
Forecast breakeven date moved forward to 2025 Dec 30
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Dec 10
Forecast breakeven date moved forward to 2025 Nov 15
Third quarter 2024 earnings released: US$0.76 loss per share (vs US$1.26 loss in 3Q 2023) Nov 13
Novavax, Inc. Revises Revenue Guidance for the Full Year 2024 Nov 13 Nov 13
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial Nov 12
Novavax, Inc Announces Update on Covid-19-Influenza Combination and Stand-Alone Influenza Phase 3 Trial Oct 16
Forecast breakeven date pushed back to 2026 Oct 11
Novavax, Inc. Updated 2024-2025 Nuvaxovid™ Covid-19 Vaccine Receives Authorization in the EU Oct 09
Novavax Announces Availability of Updated Covid-19 Vaccine with Emergency Use Authorization from FDA Sep 14
Novavax Announces That Novavax COVID-19 Vaccine, Adjuvanted Receives Emergency Use Authorization from the U.S. Food and Drug Administration Sep 05
New minor risk - Profitability Aug 12
Forecast breakeven date pushed back to 2025 Aug 09
New major risk - Shareholder dilution Aug 09 Novavax, Inc. Revises Revenue Guidance for the Full Year 2024
Novavax, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine Jun 15
Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024 May 25
President of Research & Development recently sold €355k worth of stock May 17
Novavax, Inc. Revises Revenue Guidance for the Full Year 2024 May 11
First quarter 2024 earnings released: US$1.06 loss per share (vs US$3.41 loss in 1Q 2023) May 11
Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024 May 10
Novavax, Inc., Annual General Meeting, Jun 13, 2024 May 01
New minor risk - Profitability Apr 12
No longer forecast to breakeven Apr 12
New major risk - Shareholder dilution Mar 01
Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024 Feb 29
Full year 2023 earnings released: US$5.41 loss per share (vs US$8.42 loss in FY 2022) Feb 29
New minor risk - Profitability Feb 29 Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024
Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older Dec 19
Novavax, Inc. Announces Changes to Executive Leadership Team Nov 18
New major risk - Shareholder dilution Nov 10 Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024
New minor risk - Financial position Nov 10
Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022) Nov 10
No longer forecast to breakeven Nov 09
Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU Nov 01
New minor risk - Profitability Oct 30
Forecast to breakeven in 2024 Oct 25 Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom
Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants Aug 23
No longer forecast to breakeven Aug 10 Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.
Second quarter 2023 earnings released: EPS: US$0.65 (vs US$6.53 loss in 2Q 2022) Aug 09
Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
New minor risk - Profitability Aug 01
New minor risk - Profitability Jul 14
Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid Jul 07 Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index
Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU May 27
No longer forecast to breakeven May 11
Novavax, Inc. Provides Earnings Guidance for the Full Year 2023 May 10
First quarter 2023 earnings released: US$3.41 loss per share (vs US$2.66 profit in 1Q 2022) May 09
No longer forecast to breakeven Apr 13
No longer forecast to breakeven Mar 05
Full year 2022 earnings released: US$8.42 loss per share (vs US$23.44 loss in FY 2021) Mar 01
High number of new directors Feb 01 Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth Jan 21
Novavax, Inc. Announces Chief Executive Officer Changes
Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Dec 31 Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million. Dec 17
Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million. Dec 16
Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022 Dec 15
Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee Dec 10
Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents Dec 08
No longer forecast to breakeven Dec 07
Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19 Nov 30
Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults Nov 19
Third quarter 2022 earnings released: US$2.15 loss per share (vs US$4.31 loss in 3Q 2021) Nov 10
Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine Nov 10 Novavax, Inc. Revises Revenue Guidance for the Year 2022 Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022 U.S. FDA Grants Emergency Use Authorization for Novavax, Inc.'s COVID-19 Vaccine, Adjuvanted as a Booster for Adults Oct 20
Novavax, Inc. Announces Positive Results from Phase 1/2 Clinical Trial of Its COVID-19-Influenza Combination (CIC) Vaccine Candidate Oct 14
Novavax, Inc. Presents Data from the Phase 3 PREVENT-19 Trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022 Oct 13 Shareholder Returns NVV1 DE Biotechs DE Market 7D 6.6% 4.0% 0.7% 1Y 85.8% -10.2% 8.4%
See full shareholder returns
Return vs Market: NVV1 exceeded the German Market which returned 8.4% over the past year.
Price Volatility Is NVV1's price volatile compared to industry and market? NVV1 volatility NVV1 Average Weekly Movement 10.1% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: NVV1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NVV1's weekly volatility has decreased from 21% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Show more Novavax, Inc. Fundamentals Summary How do Novavax's earnings and revenue compare to its market cap? NVV1 fundamental statistics Market cap €1.33b Earnings (TTM ) -€276.43m Revenue (TTM ) €858.99m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NVV1 income statement (TTM ) Revenue US$885.19m Cost of Revenue US$769.73m Gross Profit US$115.46m Other Expenses US$400.32m Earnings -US$284.86m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.78 Gross Margin 13.04% Net Profit Margin -32.18% Debt/Equity Ratio -32.2%
How did NVV1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/03 02:38 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Novavax, Inc. is covered by 25 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alec Stranahan BofA Global Research Mayank Mamtani B. Riley Securities, Inc. George Zavoico B. Riley Securities, Inc.
Show 22 more analysts 
